联合检测血清CEA、CA125、CA153在N_0期肺腺癌中的临床意义

目的探讨血清癌胚抗原(CEA)、糖类抗原125(CA125)及糖类抗原153(CA153)联合检测在淋巴结转移阴性的肺腺癌预后判断中的价值。方法收集197例淋巴结转移阴性的肺腺癌患者血清,采用美国ABBOTrAxsymx型电化学发光仪对血清CEA、CA125、CA153进行检测,并作单因素及多因素生存分析,探讨三项标志物对预后的判断意义。结果肿瘤标志物CEA、CA125、CA153检测阳性率分别为51.8%(102/197)、26.9%(53/197)和24.4%(48/197)。三项标志物联合检查至少有l项标志1次阳性的百分率为61.9%(122/197)。单因素生存分析发现CEA、CA125、CA153是影响本组患者生存的预后因素(P<0.05),比例风险Cox模型的多因素生存分析提示CEA、CA125、CA153均是影响本组患者生存的独立预后因素。结论 CEA、CA125、CA153三项标志在淋巴结阴性的肺腺癌患者中有较高的阳性率,三项标志联合检测的阳性率高于任一标志单独检测的阳性率,联合检测有助于提高肺癌诊断的准确性;其次,CEA、CA125、CA153可作为淋巴结阴性患者的预后判断指标。

The Clinical Value of Serum CEA,CA125 and CA153 Detection in 197 Patients with pN_0 Lung Adenocarcinoma

Objective To evaluate the clinical value of combined assay of serum carcinoembryonic antigen (CEA),carbohydrate antigen 125 (CA125) and earbohydrate antigen 153 (CAl53) in patients with pN0 lung adenocarcinoma.Methods We collected 197 pN0 lung adenocarcinoma patients' clinical information and the serum levels of CEA,CA125,CA153.Kaplan-Meier was used to calculate the overall survival time.Results The positive rate of CEA was 51.8% (102/197),CA125 was 26.9% (53/197),CA153 was 24.4% (48/197).The positive rate of combination of the 3 markers was 61.9%.The curative effect in the patients with positive results of CEA,CA125 or CA153 was poorer than that in the patients with negative results of 3 markers.Conclusions The positive results of CEA,CA125,CA153 are relatively high in patients with pN0 lung adenocarcinoma.The positive rate of combined assay of tumor markers is much higher than that of single marker.Combined measurement of at least three markers is considered to be useful for the diagnosis of lung cancer.